|
2. Etiologie
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4.10 Dép., diag. & prono. - Poumon
|
|
|
San Antonio’s BioAffinity Signs Licensing Deal for Cancer Diagnostic [Xconomy]
|
|
|
|
|
|
The
diagnostic would be used after a patient has already received a
positive result for lung cancer from low dose computed tomography (LDCT)
screening, bioAffinity says. LDCT screenings have a high rate of false
positive results, which can lead to anything from expensive scans to
invasive procedures such as a lung biopsy.
|
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
5. Traitements
|
|
|
New therapies could treat tissue swelling that afflicts cancer surgery patients and others [Science]
|
|
|
|
|
|
All
three lymphedema approaches face significant hurdles. Even if a
treatment does improve a patient's lymph flow, for instance, "the skin
will still be fibrous and elephantlike, and the fat is still there" says
physiologist Joseph Rutkowski. Flushing the excess lymph may eventually
reverse fibrosis and fat accumulation, he says, but "we haven't had the
means" to test it. Another issue is whether any successful treatment
will be affordable for the millions of lymphedema patients in developing
countries.
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
National Coverage Analysis of CAR-T Therapies — Policy, Evidence, and Payment [NEJM]
|
|
|
|
|
|
CAR-T
therapies have broken new ground on many fronts — they have shown
efficacy in patients who previously had few options, but they cost
multiple times what any previously approved cancer therapy costs. Their
rapid approval based on small, uncontrolled studies reflects their
promise. But they are no panacea. Ms. Kearney died a few weeks after
receiving her dose of the CAR-T therapy that cost nearly $400,000, and
she endured an extended hospital and ICU stay along the way.
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
5.6 ESMO
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.2 Implants mammaires
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
|
|
6.8 Communication
|
|
|